New Drug Tam-Peli Dramatically Extends Life for Relapsed Lung Cancer Patients

A groundbreaking new drug, tambotatug pelitecan (Tam-Peli), has shown astonishing success in extending the lives of patients with relapsed small-cell lung cancer (SCLC), a notoriously aggressive and hard-to-treat form of the disease. Results from the pivotal Phase III TAISHAN-302 trial, presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), revealed Tam-Peli more than doubled progression-free survival and significantly improved overall survival compared to topotecan, the long-standing standard of care for these patients. Patients treated with Tam-Peli experienced a median overall survival of 13.3 months versus just 9.4 months for those on topotecan, representing a significant 54% reduction in the risk of death. This is a major leap forward, as relapsed SCLC often leaves patients with very limited treatment options and a grim prognosis, with historical survival measured in mere weeks. The drug, an anti-B7-H3 antibody-drug conjugate (ADC) developed by China's MediLink Therapeutics, uses a 'smart bomb' approach, targeting cancer cells directly while sparing healthy tissue, and its positive safety profile further bolsters its potential. With these compelling Phase III results, the future looks brighter for SCLC patients. Tam-Peli has already received Breakthrough Therapy Designation from both China's CDE and the U.S. FDA for SCLC, and its New Drug Application (NDA) for relapsed SCLC has been accepted for priority review in China – a first for an ADC in this indication. Global pharmaceutical giant Roche, which holds exclusive licensing rights for Tam-Peli outside Greater China, now plans to swiftly initiate global Phase III trials, paving the way for worldwide availability and potentially redefining the treatment landscape for this challenging cancer.